Fri, Jan 16, 12:00 PM, Zacks
Is Myriad Genetics (MYGN) Worth Adding to Your Portfolio? - Analyst Blog
On Jan 14, 2015, Zacks Investment Research upgraded Myriad Genetics Inc. (MYGN) to a Zacks Rank 2 (Buy).
Mon, Jan 12, 1:00 PM, Zacks
Myriad's Tumor-Based Cancer Test Wins CE Mark, Shares Up - Analyst Blog
Myriad Genetic's (MYGN) Tumor BracAnalysis CDx has become the first ever tumor-based companion diagnostic test to receive the CE Mark in Europe.